Bill
Bill > HR5882
US HR5882
To amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements, and for other purposes.
summary
Introduced
02/12/2020
02/12/2020
In Committee
02/12/2020
02/12/2020
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
Allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
AI Summary
This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The agreements must meet certain requirements, such as not increasing projected net federal spending, and provide for installment-based payments over time. The Secretary of Health and Human Services must approve the agreements and consult with the Commissioner of Food and Drugs. The bill also includes provisions for assessments, reporting to Congress, and guidance and regulations to implement the new payment option.
Committee Categories
Business and Industry
Sponsors (7)
Kurt Schrader (D)*,
Ami Bera (D),
Jason Crow (D),
Mike Kelly (R),
Roger Marshall (R),
Markwayne Mullin (R),
David Schweikert (R),
Last Action
Referred to the House Committee on Energy and Commerce. (on 02/12/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/5882/all-info |
| BillText | https://www.congress.gov/116/bills/hr5882/BILLS-116hr5882ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr5882/BILLS-116hr5882ih.pdf.pdf |
Loading...